Tilray | TRLY - Operating Expenses


Tilray reported $237.52M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acasti Pharma USD 55.48M 7.27M Sep/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alaunos Therapeutics USD 952K 60K Jun/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
Avita Medical AUD 28.56M 534K Jun/2026
Canopy Growth CAD 98.74M 23K Jun/2026
Cronos Group USD -33.51M 78.92M Sep/2026
Dianthus Therapeutics USD 62.24M 15.25M Jun/2026
Divis Laboratories Ltd INR 22.52B 3.01B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
IQVIA Holdings USD 3.82B 2.05B Sep/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Moderna USD 1.18B 223M Sep/2026
Organigram Holdings CAD 100.45M 30.86M Jun/2026
Organon & Co USD 1.19B 187M Sep/2026
Revvity USD 604.27M 719K Sep/2026
Tectonic Therapeutic USD 24.22M 3.08M Jun/2026
Tilray USD 237.52M 17.34M Sep/2025
Viatris USD 3.49B 189.1M Sep/2026
Xeris Pharmaceuticals USD 86.93M 11.72M Jun/2026
Zealand Pharma A/S 573M 202.97M Mar/2026